PORTLAND, OR — February 9, 2017 — MolecularMD Corp., a molecular diagnostics company that accelerates oncology drug approval by providing custom companion diagnostic solutions and supporting clinical trial services for targeted cancer therapies, has announced the appointment of Frederick (Fritz) Eibel as its new Senior Vice President and Chief Marketing Officer. Mr. Eibel brings almost three decades of broad-based in vitro diagnostics (IVD) and life science experience focused primarily on new and emerging growth opportunities in the precision medicine segment. He most recently served as Senior Vice President of Wren Laboratories and focused on the commercialization of a group of novel gene expression assays designed for the prognosis, monitoring and therapy prediction for patients with neuroendocrine cancer. Mr. Eibel’s additional experience includes leadership roles at Rain Dance Technologies, Sequenom, Life Technologies, Gen Probe and over 23 years in various roles at Roche Diagnostics. He has also served on the MolecularMD Board of Directors for over four years.
“Fritz’s contribution to the Board has been of great value and the company looks forward to further leveraging his experiences and proven strategies for the successful development and commercialization of selling products in today’s Precision Medicine market segment,” said Dan Snyder, President and CEO of MolecularMD .
Partnership facilitates therapeutic biomarker and target validation, assay development and clinical trial management for companion diagnostics and drug development.
PORTLAND, OR, CAMBRIDGE, MA and DETROIT, MI – February 15, 2017- Asterand Bioscience, the leader in high quality, well-characterized human tissue and human tissue-based research solutions supporting drug discovery and development, announced today a partnership with MolecularMD to combine MolecularMD’s expertise as a provider of molecular diagnostics products and services with Asterand Bio’s drug target and candidate validation capabilities. MolecularMD is a molecular diagnostics company that develops custom clinical trial assays as well as companion diagnostic products, supporting clinical trial services and commercialization of targeted cancer therapies. The partnership creates an end-to-end workflow for biopharma clients and strengthens the companies’ current offerings in assay development & validation, while creating a global footprint for the efficient delivery of clinical trial sample analyses.
“For over 20 years, Asterand Bioscience’s experienced scientists have worked collaboratively with clients to expedite the highest likelihood for clinical success by providing a variety of pre-clinical research services,” said John Canepa, Chief Financial Officer/Chief Operations Officer. “This agreement brings together MolecularMD’s proven track record in clinical assay development and companion diagnostics with Asterand Bio’s human tissue procurement, characterization and research services to provide a comprehensive approach to meet the needs of pharmaceutical, biotechnology and diagnostic companies from validation of biomarkers and targets to assay development, through regulatory and clinical trials.”
“MolecularMD is uniquely suited to assist biopharma clients with our clinical trial and regulatory expertise,” said Dan Snyder, President/Chief Executive Officer, MolecularMD. “I’m excited that Asterand Bio and MolecularMD have joined forces to provide these unique advantages which will help our broad client base accelerate their pipeline decisions and dramatically improve the efficiency of the clinical trial and commercialization workflow.”
Asterand Bio and MolecularMD will both attend Molecular Med Tri-Con 2017, Feb 19-24 at the Moscone North Convention Center, San Francisco, CA, a meeting bringing together over 3,500 drug discovery and development professionals. More information about the partnership can be found at Asterand Bio’s booth #626. Asterand Bio and MolecularMD will both attend the AACR 2017 meeting, April 1-5 at the Walter E. Washington Convention Center in Washington DC, a meeting that highlights the highest level of cancer science and medicine from institutions all over the world. More information about the partnership can be found at Asterand Bio’s booth #1340 and MolecularMD’s booth #3423.
PORTLAND, OR and CAMBRIDGE, MA – June 27, 2016 – MolecularMD Corporation announced today that it has entered into an agreement with Illumina, Inc. (NASDAQ: ILMN) that establishes a framework for potential collaborations with respect to the development and commercialization of sequencing-based companion diagnostics in support of biopharma drug development program(s). The agreement dovetails MolecularMD’s companion diagnostic development and FDA submission experience with Illumina’s NGS technology.
“This agreement is designed to deliver the combined power of Illumina’s NGS technologies with MolecularMD’s ability to tailor a complete clinical development solution including regulatory planning, IDE validations and centralized testing and data management for global patient enrollment and disease monitoring,” stated Dan Snyder, CEO of MolecularMD.
MolecularMD opened its advanced diagnostic laboratory in Cambridge, MA in 2012 with the objective of providing NGS solutions that support clinical trials of oncology drug programs. MolecularMD has since deployed NGS diagnostics over a broad range of drug targets and indications. The ability to support global trials with centralized testing laboratories while simultaneously obtaining necessary regulatory compliance can allow rapid deployment of Illumina based NGS solutions.
“Our goal is to enable our clients with the latest platforms and proven technologies that solve for the challenges that often arise during drug and diagnostic co-development,” stated Snyder. “The ability to collaborate with Illumina on defined projects will greatly aid our clients to mitigate risks and to accelerate their clinical trial programs.”
Partnership Provides State-of-the-Art Patient Stratification Using Quantitative Tissue Assays For
Clinical Development and Diagnostics
Munich, Germany – June 2, 2016 – Definiens, the pioneer in Tissue Phenomics solutions for
diagnostics development and commercialization, today announced a partnership agreement
with MolecularMD to combine MolecularMD’s expertise in specialty diagnostic assays with
Definiens’ quantitative tissue read-outs. MolecularMD is a molecular diagnostics company that
develops custom companion diagnostic products and supports clinical trial services for targeted
“Definiens’ technology already empowers smarter tissue-based diagnostics,” said Merrilyn
Datta, chief commercial officer, Definiens. “This agreement brings together MolecularMD’s
proven track record in clinical assay development and companion diagnostics with Definiens’
unparalleled image analysis platform to provide the confidence of an integrated solution in
The new partnership between the two diagnostics companies provides custom solutions that
meet data and regulatory requirements for both biopharmaceutical clients and academic
medical center oncology programs, including advanced solutions with assays, image analysis
and data mining, combined with deep scientific, regulatory and pathology support.
“MolecularMD is uniquely suited to assist biopharmaceutical clients and academic medical
centers with our clinical trial and regulatory expertise,” said Dan Snyder, president and chief
executive officer, MolecularMD. “I’m thrilled that Definiens and MolecularMD have joined
forces to provide these unique advantages, accelerating pipeline decisions and dramatically
improving patient stratification from the pre-clinical phase.”
PORTLAND, OR and CAMBRIDGE, MA – April 25, 2016 – MolecularMD Corp., a molecular diagnostics company that accelerates oncology drug development by providing custom companion diagnostic solutions and supporting clinical trial services for targeted cancer therapies, has partnered with Daiichi Sankyo, Inc. on their work in developing oncology compounds. In collaboration with Daiichi Sankyo, MolecularMD has validated a clinical trial assay that will be used to enrich the patient population for a Phase II clinical trial which is commencing in Europe. MolecularMD has completed the CE registration with the European authorities to ensure future access as an assay, which is to be used for patient selection into the trial.
“Identifying the precise subset of patients who may respond to our compound helps to fully assess its potential efficacy and safety profile,” said Antoine Yver, MD, MSc, Executive VP and Global Head, Oncology R&D, Daiichi Sankyo.
“MolecularMD is entirely focused on accelerating development of precision oncology medicines. Our work with Daiichi Sankyo demonstrates our ability to support a wide spectrum of clinical and regulatory strategies, stated Dan Snyder, CEO of MolecularMD. “We have a long standing and successful collaboration with their team”. The arrangement with Daiichi Sankyo represents just one of MolecularMD’s Master Service Agreements among the top 25 prominent BioPharma companies in the Industry.